Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

Results showed the immunotherapy combination led to a 38 ... drug conjugate designed to target the cancer protein TROP2. —Imfinzi also added perioperative treatment of muscle invasive bladder ...

While immunotherapy has transformed the treatment ... At ASCO, AZ reported the full data from its DUO-O study of PD-L1 inhibitor Imfinzi (durvalumab) as a combination regimen with its PARP ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

The immunotherapy improved outcomes compared ... a phase 3 trial comparing tarlatamab in combination with durvalumab (Imfinzi; AstraZeneca) to durvalumab alone as first-line maintenance therapy ...

Immunotherapy is the use of medicines that help a person ... Atezolizumab (Tecentriq) and durvalumab (Imfinzi) target the PD-L1 protein. Blocking this protein can help boost the immune response ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...